These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 19622454)

  • 1. Cefditoren versus community-acquired respiratory pathogens: time-kill studies.
    Mezzatesta ML; Gona F; Marchese G; Nicolosi D; Toscano MA; Stefani S; Nicoletti G
    J Chemother; 2009 Aug; 21(4):378-82. PubMed ID: 19622454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of cefditoren and other comparators against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis causing community-acquired respiratory tract infections in China.
    Yang Q; Xu Y; Chen M; Wang H; Sun H; Hu Y; Zhang R; Duan Q; Zhuo C; Cao B; Liu Y; Yu Y; Sun Z; Chu Y
    Diagn Microbiol Infect Dis; 2012 Jun; 73(2):187-91. PubMed ID: 22521692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibacterial activity of cefditoren against major community-acquired respiratory pathogens recently isolated in Italy.
    Stefani S; Mezzatesta ML; Fadda G; Mattina R; Palù G; Rossano F; Tufano MA; Schito GC; Nicoletti G
    J Chemother; 2008 Oct; 20(5):561-9. PubMed ID: 19028617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibiotic susceptibility of respiratory pathogens recently isolated in Italy: focus on cefditoren.
    Tempera G; Furneri PM; Carlone NA; Cocuzza C; Rigoli R; Musumeci R; Pilloni AP; Prenna M; Tufano MA; Tullio V; Vitali LA; Nicoletti G
    J Chemother; 2010 Jun; 22(3):153-9. PubMed ID: 20566418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update of cefditoren activity tested against community-acquired pathogens associated with infections of the respiratory tract and skin and skin structures, including recent pharmacodynamic considerations.
    Biedenbach DJ; Jones RN
    Diagn Microbiol Infect Dis; 2009 Jun; 64(2):202-12. PubMed ID: 19321284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials.
    Granizo JJ; Giménez MJ; Barberán J; Coronel P; Gimeno M; Aguilar L
    Clin Ther; 2006 Dec; 28(12):2061-9. PubMed ID: 17296462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro study of the post-antibiotic effect and the bactericidal activity of Cefditoren and ten other oral antimicrobial agents against upper and lower respiratory tract pathogens.
    Dubois J; St-Pierre C
    Diagn Microbiol Infect Dis; 2000 Jul; 37(3):187-93. PubMed ID: 10904192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antimicrobial activity of cefditoren tested against contemporary (2004-2006) isolates of Haemophilus influenzae and Moraxella catarrhalis responsible for community-acquired respiratory tract infections in the United States.
    Biedenbach DJ; Jones RN; Fritsche TR
    Diagn Microbiol Infect Dis; 2008 Jun; 61(2):240-4. PubMed ID: 18353594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cefditoren in vitro activity and spectrum: a review of international studies using reference methods.
    Jones RN; Pfaller MA; Jacobs MR; Appelbaum PC; Fuchs PC
    Diagn Microbiol Infect Dis; 2001; 41(1-2):1-14. PubMed ID: 11687308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity of cefditoren and other antimicrobial agents against 288 Streptococcus pneumoniae and 220 Haemophilus influenzae clinical strains isolated in Zaragoza, Spain.
    Seral C; Suárez L; Rubio-Calvo C; Gómez-Lus R; Gimeno M; Coronel P; Durán E; Becerril R; Oca M; Castillo FJ
    Diagn Microbiol Infect Dis; 2008 Oct; 62(2):210-5. PubMed ID: 18715733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cefditoren and community-acquired lower respiratory tract infections (corrected)].
    Barberán J; Mensa J
    Rev Esp Quimioter; 2009 Sep; 22(3):144-50. PubMed ID: 19662548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update of the activity of cefditoren and comparator oral beta-lactam agents tested against community-acquired Streptococcus pneumoniae isolates (USA, 2004-2006).
    Fritsche TR; Biedenbach DJ; Jones RN
    J Chemother; 2008 Apr; 20(2):170-4. PubMed ID: 18467241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Resistance study of community respiratory pathogens isolated in China from 2005 to 2007].
    Sun HL; Yang QW; Xu YC; Wang H; Xie XL; Chen MJ; Zhang XZ; Liu Y; Ye HF; Sun ZY; Duan Q; Ni YX; Yu YS; Zhao WS; He L; Wang J; Ji P; Liu PP; Zhang LX
    Zhonghua Yi Xue Za Zhi; 2009 Nov; 89(42):2983-7. PubMed ID: 20137709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro antimicrobial activity of cefditoren and other oral antibiotics against Streptococcus pneumoniae, isolated from children with community acquired respiratory tract infections.
    Kang JH; Lee SY; Kim JH; Hur JK; Lee KY
    Jpn J Antibiot; 2010 Feb; 63(1):11-7. PubMed ID: 20836403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Antimicrobial susceptibility of community-acquired respiratory tract pathogens isolated from adults in China during 2009 and 2010].
    Wang H; Liu YL; Chen MJ; Xu YC; Sun HL; Yang QW; Hu YJ; Cao B; Chu YZ; Liu Y; Zhang R; Yu YS; Sun ZY; Zhuo C; Ni YX; Hu BJ
    Zhonghua Jie He He Hu Xi Za Zhi; 2012 Feb; 35(2):113-9. PubMed ID: 22455967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhibiting an N526K mutation in the ftsI gene.
    Torrico M; Aguilar L; González N; Giménez MJ; Echeverría O; Cafini F; Sevillano D; Alou L; Coronel P; Prieto J
    Antimicrob Agents Chemother; 2007 Oct; 51(10):3699-706. PubMed ID: 17664320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of cefditoren pivoxil and amoxicillin/ clavulanate in the treatment of community-acquired pneumonia: a multicenter, prospective, randomized, investigator-blinded, parallel-group study.
    Fogarty CM; Cyganowski M; Palo WA; Hom RC; Craig WA
    Clin Ther; 2002 Nov; 24(11):1854-70. PubMed ID: 12501879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review of the spectrum and potency of orally administered cephalosporins and amoxicillin/clavulanate.
    Sader HS; Jacobs MR; Fritsche TR
    Diagn Microbiol Infect Dis; 2007 Mar; 57(3 Suppl):5S-12S. PubMed ID: 17292577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent.
    White AR; Kaye C; Poupard J; Pypstra R; Woodnutt G; Wynne B
    J Antimicrob Chemother; 2004 Jan; 53 Suppl 1():i3-20. PubMed ID: 14726431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of the beta-lactam resistance phenotype on the cefuroxime versus cefditoren susceptibility of Streptococcus pneumoniae and Haemophilus influenzae recovered from children with acute otitis media.
    Fenoll A; Aguilar L; Robledo O; Giménez MJ; Tarragó D; Granizo JJ; Gimeno M; Coronel P
    J Antimicrob Chemother; 2007 Aug; 60(2):323-7. PubMed ID: 17562681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.